Inventor
Michael ASENSIO
Inventor
US
Overview
Patents· 7 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Kprimary
A61KPreparations for medical, dental or toiletry purposes20%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations20%
C07KPeptides20%
C12NMicroorganisms or enzymes14%
C40BCombinatorial chemistry14%
Y02ATechnologies for adaptation to climate change11%
PatentTitleYear
12,590,386Recombinant polyclonal proteins and methods of use thereof202612,497,711Engineered cells expressing anti-viral T cell receptors and methods of use thereof202512,421,311Anti-CTLA-4 binding proteins and methods of use thereof202512,404,607Recombinant polyclonal proteins targeting COVID-19 and methods of use thereof202511,718,660Recombinant polyclonal proteins targeting Zika and methods of use thereof202311,685,779Recombinant polyclonal proteins targeting COVID-19 and methods of use thereof202311,421,220Engineered cells expressing anti-viral T cell receptors and methods of use thereof2022Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2022–2025Patents assigned to GIGAMUNE INC (2)· patent assignee history
2022–2026Based in US· patent location history
2023–2026Patents assigned to GIGAGEN INC (5)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| GIGAGEN INC | 5 | 2023–2026 |
| GIGAMUNE INC | 2 | 2022–2025 |
Locations
| Location | Patents | Span |
|---|---|---|
| US | 7 | 2022–2026 |